Share Price and Basic Stock Data
Last Updated: January 17, 2026, 6:49 am
| PEG Ratio | 112.06 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
ERIS Lifesciences Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹20,045 Cr and a share price of ₹1,472. The company reported a revenue from operations of ₹1,685 Cr for the fiscal year ending March 2023, which rose significantly to ₹2,009 Cr in March 2024, reflecting a robust growth trajectory. The trailing twelve-month (TTM) revenue stood at ₹2,998 Cr, demonstrating consistent revenue generation. Quarterly sales also indicate an upward trend, with ₹505 Cr recorded in September 2023, compared to ₹461 Cr in September 2022. This growth trend highlights ERIS’s ability to expand its market presence effectively. The operating profit margin (OPM) for the latest quarter stood at 36%, showcasing strong operational efficiency. As the company continues to scale, the effective management of expenses will be critical, particularly as expenses rose to ₹1,876 Cr in March 2025 from ₹1,332 Cr in March 2024, indicating a need for careful cost control to maintain profitability.
Profitability and Efficiency Metrics
ERIS Lifesciences’ profitability metrics reflect a mixed performance. The net profit for the fiscal year ending March 2025 was ₹375 Cr, which is a decline from ₹397 Cr in March 2024. Despite this, the net profit margin stood at 12.94%, indicating solid profitability relative to sales. The interest coverage ratio (ICR) was reported at 4.48x, suggesting that the company is well-positioned to meet its interest obligations, although this is lower than previous years, where it peaked at 20.94x in March 2023. The return on equity (ROE) was recorded at 12.9%, while return on capital employed (ROCE) stood at 12.2%, both of which are moderate compared to industry standards. Furthermore, the cash conversion cycle (CCC) was reported at 59 days, reflecting an efficient working capital management strategy. However, the increase in borrowing to ₹2,389 Cr raises concerns about leveraging, which could impact future profitability if not managed effectively.
Balance Sheet Strength and Financial Ratios
The balance sheet of ERIS Lifesciences demonstrates a growing reserve base, which stood at ₹3,078 Cr as of September 2025, up from ₹2,841 Cr in March 2025. Borrowings have also increased significantly, rising from ₹2,478 Cr in March 2025 to ₹2,389 Cr, reflecting a strategic choice to finance growth through debt. The total liabilities amounted to ₹7,160 Cr, and the total assets were reported at ₹7,160 Cr, indicating a balanced financial structure. The company’s current ratio was 0.88x, which is below the typical sector benchmark of 1.0x, suggesting potential liquidity constraints. The price-to-book value (P/BV) ratio was recorded at 6.76x, indicating that the stock may be overvalued compared to its book value. Additionally, the operating profit margin (OPM) for the last fiscal year stood at 35.78%, indicating consistent operational efficiency, although the rising depreciation expenses, which reached ₹315 Cr in March 2025, could impact future profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of ERIS Lifesciences reflects a stable investor base, with promoters holding 54.85% of the shares. Foreign institutional investors (FIIs) have decreased their stake to 7.21%, down from a high of 15.50% in December 2022, indicating a potential shift in investor sentiment. Domestic institutional investors (DIIs) increased their holdings to 19.36%, which may signal confidence in the company’s long-term prospects. The total number of shareholders rose to 59,438, indicating growing retail interest. The dividend payout ratio for the fiscal year ending March 2025 was 28.43%, an increase from previous years, suggesting a commitment to returning value to shareholders. However, the decrease in FIIs and the relatively high P/BV ratio compared to sector norms may raise concerns regarding valuation and long-term growth expectations. This mixed sentiment underscores the need for the company to enhance its operational performance to sustain investor confidence.
Outlook, Risks, and Final Insight
ERIS Lifesciences faces a dual-edged outlook. On one hand, the company has demonstrated strong revenue growth and operational efficiency, with a robust OPM of 36%. On the other hand, the decline in net profit and the increased debt levels pose significant risks. The rising interest expenses, which escalated to ₹231 Cr in March 2025, could pressure profitability if sales growth does not keep pace. Additionally, the declining ICR indicates potential vulnerabilities in financial stability. Investors should monitor the company’s ability to manage expenses and leverage effectively. The pharmaceutical sector’s inherent volatility, regulatory challenges, and competitive landscape could also impact ERIS’s growth trajectory. Overall, while the fundamentals remain strong, the company must navigate these challenges to sustain its growth momentum and maintain investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 205/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,910 Cr. | 356 | 479/192 | 81.0 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,986.97 Cr | 1,115.98 | 52.27 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 461 | 423 | 403 | 467 | 505 | 486 | 551 | 720 | 741 | 727 | 705 | 773 | 792 |
| Expenses | 309 | 286 | 284 | 297 | 324 | 311 | 402 | 470 | 477 | 477 | 453 | 496 | 504 |
| Operating Profit | 151 | 137 | 119 | 170 | 181 | 176 | 148 | 250 | 265 | 250 | 252 | 277 | 288 |
| OPM % | 33% | 32% | 30% | 36% | 36% | 36% | 27% | 35% | 36% | 34% | 36% | 36% | 36% |
| Other Income | 5 | 2 | 1 | 1 | 3 | 4 | 15 | 2 | 5 | 4 | 8 | 4 | 3 |
| Interest | 7 | 3 | 9 | 17 | 16 | 18 | 33 | 60 | 59 | 57 | 54 | 49 | 50 |
| Depreciation | 29 | 30 | 35 | 41 | 42 | 46 | 54 | 76 | 80 | 81 | 77 | 71 | 69 |
| Profit before tax | 121 | 107 | 76 | 112 | 126 | 116 | 77 | 116 | 129 | 116 | 129 | 161 | 173 |
| Tax % | 1% | 6% | 19% | 17% | 3% | 12% | -4% | 22% | 25% | 25% | 21% | 22% | 22% |
| Net Profit | 119 | 100 | 61 | 94 | 122 | 101 | 80 | 90 | 96 | 87 | 102 | 125 | 134 |
| EPS in Rs | 8.85 | 7.49 | 4.81 | 6.98 | 9.07 | 7.55 | 5.22 | 6.12 | 6.73 | 6.15 | 6.89 | 8.66 | 8.82 |
Last Updated: January 1, 2026, 8:36 pm
Below is a detailed analysis of the quarterly data for ERIS Lifesciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 792.00 Cr.. The value appears strong and on an upward trend. It has increased from 773.00 Cr. (Jun 2025) to 792.00 Cr., marking an increase of 19.00 Cr..
- For Expenses, as of Sep 2025, the value is 504.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 496.00 Cr. (Jun 2025) to 504.00 Cr., marking an increase of 8.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 288.00 Cr.. The value appears strong and on an upward trend. It has increased from 277.00 Cr. (Jun 2025) to 288.00 Cr., marking an increase of 11.00 Cr..
- For OPM %, as of Sep 2025, the value is 36.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 36.00%.
- For Other Income, as of Sep 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Jun 2025) to 3.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 50.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 49.00 Cr. (Jun 2025) to 50.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 69.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 71.00 Cr. (Jun 2025) to 69.00 Cr., marking a decrease of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 173.00 Cr.. The value appears strong and on an upward trend. It has increased from 161.00 Cr. (Jun 2025) to 173.00 Cr., marking an increase of 12.00 Cr..
- For Tax %, as of Sep 2025, the value is 22.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 22.00%.
- For Net Profit, as of Sep 2025, the value is 134.00 Cr.. The value appears strong and on an upward trend. It has increased from 125.00 Cr. (Jun 2025) to 134.00 Cr., marking an increase of 9.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 8.82. The value appears strong and on an upward trend. It has increased from 8.66 (Jun 2025) to 8.82, marking an increase of 0.16.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:24 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 509 | 546 | 597 | 750 | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,685 | 2,009 | 2,894 | 2,998 |
| Expenses | 414 | 427 | 425 | 480 | 533 | 637 | 702 | 781 | 858 | 1,146 | 1,332 | 1,876 | 1,931 |
| Operating Profit | 95 | 118 | 172 | 269 | 322 | 345 | 372 | 431 | 489 | 539 | 677 | 1,018 | 1,068 |
| OPM % | 19% | 22% | 29% | 36% | 38% | 35% | 35% | 36% | 36% | 32% | 34% | 35% | 36% |
| Other Income | 9 | 7 | 3 | 25 | 26 | 31 | 12 | 9 | 22 | 9 | 22 | 18 | 19 |
| Interest | 0 | 0 | 0 | 1 | 11 | 23 | 2 | 2 | 4 | 26 | 85 | 231 | 210 |
| Depreciation | 5 | 16 | 20 | 23 | 26 | 36 | 50 | 43 | 65 | 117 | 183 | 315 | 298 |
| Profit before tax | 98 | 109 | 154 | 270 | 312 | 317 | 331 | 394 | 442 | 405 | 431 | 489 | 579 |
| Tax % | 28% | 18% | 13% | 9% | 6% | 8% | 11% | 10% | 8% | 8% | 8% | 23% | |
| Net Profit | 71 | 89 | 135 | 247 | 295 | 291 | 297 | 355 | 406 | 374 | 397 | 375 | 449 |
| EPS in Rs | 5,121.45 | 6,489.45 | 9,714.18 | 17.95 | 21.39 | 21.15 | 21.84 | 26.16 | 29.88 | 28.10 | 28.82 | 25.84 | 30.52 |
| Dividend Payout % | -0% | -0% | 63% | -0% | -0% | -0% | 13% | 21% | 20% | 26% | -0% | 28% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 25.35% | 51.69% | 82.96% | 19.43% | -1.36% | 2.06% | 19.53% | 14.37% | -7.88% | 6.15% | -5.54% |
| Change in YoY Net Profit Growth (%) | 0.00% | 26.33% | 31.28% | -63.53% | -20.79% | 3.42% | 17.47% | -5.16% | -22.25% | 14.03% | -11.69% |
ERIS Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 22% |
| 3 Years: | 29% |
| TTM: | 30% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 4% |
| 3 Years: | -5% |
| TTM: | 2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 37% |
| 1 Year: | 21% |
| Return on Equity | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 18% |
| 3 Years: | 16% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 3:40 am
Balance Sheet
Last Updated: January 7, 2026, 3:38 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.14 | 0.14 | 0.14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 176 | 266 | 299 | 553 | 848 | 1,137 | 1,283 | 1,563 | 1,895 | 2,182 | 2,573 | 2,841 | 3,078 |
| Borrowings | 1 | 1 | 0 | 1 | 377 | 176 | -0 | 7 | 84 | 877 | 2,781 | 2,478 | 2,389 |
| Other Liabilities | 94 | 91 | 98 | 124 | 170 | 175 | 205 | 202 | 233 | 337 | 1,366 | 1,412 | 1,680 |
| Total Liabilities | 271 | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,734 | 6,744 | 7,160 |
| Fixed Assets | 75 | 72 | 71 | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 4,319 | 5,306 | 5,217 |
| CWIP | -0 | -0 | -0 | 0 | -0 | 3 | 4 | 2 | 27 | 22 | 20 | 67 | 122 |
| Investments | 84 | 167 | 190 | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 | 67 | 68 |
| Other Assets | 112 | 119 | 136 | 157 | 271 | 383 | 544 | 636 | 761 | 783 | 2,379 | 1,304 | 1,753 |
| Total Assets | 271 | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,734 | 6,744 | 7,160 |
Below is a detailed analysis of the balance sheet data for ERIS Lifesciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,078.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,841.00 Cr. (Mar 2025) to 3,078.00 Cr., marking an increase of 237.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,389.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,478.00 Cr. (Mar 2025) to 2,389.00 Cr., marking a decrease of 89.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,680.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,412.00 Cr. (Mar 2025) to 1,680.00 Cr., marking an increase of 268.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 7,160.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,744.00 Cr. (Mar 2025) to 7,160.00 Cr., marking an increase of 416.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 5,217.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,306.00 Cr. (Mar 2025) to 5,217.00 Cr., marking a decrease of 89.00 Cr..
- For CWIP, as of Sep 2025, the value is 122.00 Cr.. The value appears strong and on an upward trend. It has increased from 67.00 Cr. (Mar 2025) to 122.00 Cr., marking an increase of 55.00 Cr..
- For Investments, as of Sep 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 67.00 Cr. (Mar 2025) to 68.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,753.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,304.00 Cr. (Mar 2025) to 1,753.00 Cr., marking an increase of 449.00 Cr..
- For Total Assets, as of Sep 2025, the value is 7,160.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,744.00 Cr. (Mar 2025) to 7,160.00 Cr., marking an increase of 416.00 Cr..
Notably, the Reserves (3,078.00 Cr.) exceed the Borrowings (2,389.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 94.00 | 117.00 | 172.00 | 268.00 | -55.00 | 169.00 | 372.00 | 424.00 | 405.00 | -338.00 | 675.00 | -1.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 16 | 16 | 16 | 24 | 28 | 31 | 53 | 42 | 44 | 63 | 77 | 58 |
| Inventory Days | 166 | 223 | 178 | 195 | 178 | 196 | 148 | 145 | 166 | 136 | 182 | 171 |
| Days Payable | 138 | 142 | 92 | 134 | 247 | 200 | 213 | 157 | 166 | 129 | 210 | 170 |
| Cash Conversion Cycle | 43 | 97 | 102 | 84 | -40 | 28 | -12 | 30 | 44 | 70 | 48 | 59 |
| Working Capital Days | 7 | 15 | 9 | 23 | -13 | -17 | 59 | 64 | 75 | 50 | -296 | -49 |
| ROCE % | 64% | 47% | 53% | 60% | 34% | 26% | 25% | 27% | 25% | 17% | 11% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund | 6,482,100 | 2.72 | 1034.15 | N/A | N/A | N/A |
| HDFC Hybrid Equity Fund | 2,459,629 | 1.59 | 392.41 | N/A | N/A | N/A |
| Franklin India Small Cap Fund | 1,866,828 | 2.2 | 297.83 | N/A | N/A | N/A |
| DSP Small Cap Fund | 1,230,000 | 1.15 | 196.23 | N/A | N/A | N/A |
| Franklin India Flexi Cap Fund | 1,224,569 | 0.98 | 195.37 | N/A | N/A | N/A |
| UTI Flexi Cap Fund | 1,217,751 | 0.76 | 194.28 | 2,573,067 | 2025-12-07 01:12:50 | -52.67% |
| Franklin India Opportunities Fund | 771,388 | 1.48 | 123.07 | N/A | N/A | N/A |
| HDFC Large and Mid Cap Fund | 675,000 | 0.37 | 107.69 | N/A | N/A | N/A |
| HDFC Multi Cap Fund | 675,000 | 0.54 | 107.69 | N/A | N/A | N/A |
| UTI Mid Cap Fund | 643,678 | 0.85 | 102.69 | 627,981 | 2025-12-15 01:01:34 | 2.5% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 25.85 | 28.82 | 28.10 | 29.89 | 26.16 |
| Diluted EPS (Rs.) | 25.81 | 28.79 | 28.07 | 29.88 | 26.14 |
| Cash EPS (Rs.) | 50.67 | 42.61 | 36.12 | 34.61 | 29.32 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 209.57 | 190.11 | 163.30 | 140.35 | 116.10 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 209.57 | 190.11 | 163.30 | 140.35 | 116.10 |
| Revenue From Operations / Share (Rs.) | 212.46 | 147.70 | 123.92 | 99.10 | 89.25 |
| PBDIT / Share (Rs.) | 76.03 | 51.36 | 40.29 | 37.60 | 32.35 |
| PBIT / Share (Rs.) | 52.87 | 37.94 | 31.68 | 32.84 | 29.19 |
| PBT / Share (Rs.) | 35.89 | 31.70 | 29.76 | 32.53 | 29.05 |
| Net Profit / Share (Rs.) | 27.50 | 29.19 | 27.51 | 29.85 | 26.16 |
| NP After MI And SOA / Share (Rs.) | 25.83 | 28.82 | 28.10 | 29.88 | 26.16 |
| PBDIT Margin (%) | 35.78 | 34.77 | 32.51 | 37.93 | 36.24 |
| PBIT Margin (%) | 24.88 | 25.68 | 25.56 | 33.13 | 32.70 |
| PBT Margin (%) | 16.89 | 21.46 | 24.01 | 32.82 | 32.55 |
| Net Profit Margin (%) | 12.94 | 19.76 | 22.20 | 30.12 | 29.30 |
| NP After MI And SOA Margin (%) | 12.15 | 19.50 | 22.67 | 30.14 | 29.30 |
| Return on Networth / Equity (%) | 12.32 | 15.15 | 17.40 | 21.28 | 22.52 |
| Return on Capital Employeed (%) | 12.74 | 11.42 | 13.36 | 21.53 | 23.76 |
| Return On Assets (%) | 5.00 | 5.56 | 10.42 | 17.87 | 19.35 |
| Long Term Debt / Equity (X) | 0.60 | 0.25 | 0.29 | 0.02 | 0.00 |
| Total Debt / Equity (X) | 0.84 | 1.06 | 0.37 | 0.02 | 0.00 |
| Asset Turnover Ratio (%) | 0.41 | 0.37 | 0.52 | 0.61 | 0.67 |
| Current Ratio (X) | 0.88 | 0.90 | 1.73 | 3.14 | 2.80 |
| Quick Ratio (X) | 0.64 | 0.83 | 1.43 | 2.55 | 2.23 |
| Inventory Turnover Ratio (X) | 11.05 | 1.11 | 1.26 | 1.31 | 1.48 |
| Dividend Payout Ratio (NP) (%) | 28.43 | 0.00 | 26.15 | 20.10 | 21.02 |
| Dividend Payout Ratio (CP) (%) | 14.99 | 0.00 | 20.01 | 17.34 | 18.75 |
| Earning Retention Ratio (%) | 71.57 | 0.00 | 73.85 | 79.90 | 78.98 |
| Cash Earning Retention Ratio (%) | 85.01 | 0.00 | 79.99 | 82.66 | 81.25 |
| Interest Coverage Ratio (X) | 4.48 | 8.24 | 20.94 | 123.26 | 243.78 |
| Interest Coverage Ratio (Post Tax) (X) | 2.62 | 5.68 | 15.30 | 98.87 | 198.08 |
| Enterprise Value (Cr.) | 21908.96 | 13413.39 | 8575.56 | 9359.51 | 8168.96 |
| EV / Net Operating Revenue (X) | 7.57 | 6.68 | 5.09 | 6.95 | 6.74 |
| EV / EBITDA (X) | 21.16 | 19.20 | 15.65 | 18.31 | 18.60 |
| MarketCap / Net Operating Revenue (X) | 6.67 | 5.70 | 4.62 | 6.95 | 6.77 |
| Retention Ratios (%) | 71.56 | 0.00 | 73.84 | 79.89 | 78.97 |
| Price / BV (X) | 6.76 | 4.42 | 3.54 | 4.91 | 5.21 |
| Price / Net Operating Revenue (X) | 6.67 | 5.70 | 4.62 | 6.95 | 6.77 |
| EarningsYield | 0.01 | 0.03 | 0.04 | 0.04 | 0.04 |
After reviewing the key financial ratios for ERIS Lifesciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 25.85. This value is within the healthy range. It has decreased from 28.82 (Mar 24) to 25.85, marking a decrease of 2.97.
- For Diluted EPS (Rs.), as of Mar 25, the value is 25.81. This value is within the healthy range. It has decreased from 28.79 (Mar 24) to 25.81, marking a decrease of 2.98.
- For Cash EPS (Rs.), as of Mar 25, the value is 50.67. This value is within the healthy range. It has increased from 42.61 (Mar 24) to 50.67, marking an increase of 8.06.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 209.57. It has increased from 190.11 (Mar 24) to 209.57, marking an increase of 19.46.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 209.57. It has increased from 190.11 (Mar 24) to 209.57, marking an increase of 19.46.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 212.46. It has increased from 147.70 (Mar 24) to 212.46, marking an increase of 64.76.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 76.03. This value is within the healthy range. It has increased from 51.36 (Mar 24) to 76.03, marking an increase of 24.67.
- For PBIT / Share (Rs.), as of Mar 25, the value is 52.87. This value is within the healthy range. It has increased from 37.94 (Mar 24) to 52.87, marking an increase of 14.93.
- For PBT / Share (Rs.), as of Mar 25, the value is 35.89. This value is within the healthy range. It has increased from 31.70 (Mar 24) to 35.89, marking an increase of 4.19.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 27.50. This value is within the healthy range. It has decreased from 29.19 (Mar 24) to 27.50, marking a decrease of 1.69.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 25.83. This value is within the healthy range. It has decreased from 28.82 (Mar 24) to 25.83, marking a decrease of 2.99.
- For PBDIT Margin (%), as of Mar 25, the value is 35.78. This value is within the healthy range. It has increased from 34.77 (Mar 24) to 35.78, marking an increase of 1.01.
- For PBIT Margin (%), as of Mar 25, the value is 24.88. This value exceeds the healthy maximum of 20. It has decreased from 25.68 (Mar 24) to 24.88, marking a decrease of 0.80.
- For PBT Margin (%), as of Mar 25, the value is 16.89. This value is within the healthy range. It has decreased from 21.46 (Mar 24) to 16.89, marking a decrease of 4.57.
- For Net Profit Margin (%), as of Mar 25, the value is 12.94. This value exceeds the healthy maximum of 10. It has decreased from 19.76 (Mar 24) to 12.94, marking a decrease of 6.82.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.15. This value is within the healthy range. It has decreased from 19.50 (Mar 24) to 12.15, marking a decrease of 7.35.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.32. This value is below the healthy minimum of 15. It has decreased from 15.15 (Mar 24) to 12.32, marking a decrease of 2.83.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.74. This value is within the healthy range. It has increased from 11.42 (Mar 24) to 12.74, marking an increase of 1.32.
- For Return On Assets (%), as of Mar 25, the value is 5.00. This value is within the healthy range. It has decreased from 5.56 (Mar 24) to 5.00, marking a decrease of 0.56.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.60. This value is within the healthy range. It has increased from 0.25 (Mar 24) to 0.60, marking an increase of 0.35.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.84. This value is within the healthy range. It has decreased from 1.06 (Mar 24) to 0.84, marking a decrease of 0.22.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.41. It has increased from 0.37 (Mar 24) to 0.41, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1.5. It has decreased from 0.90 (Mar 24) to 0.88, marking a decrease of 0.02.
- For Quick Ratio (X), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 1. It has decreased from 0.83 (Mar 24) to 0.64, marking a decrease of 0.19.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 11.05. This value exceeds the healthy maximum of 8. It has increased from 1.11 (Mar 24) to 11.05, marking an increase of 9.94.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 28.43. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 28.43, marking an increase of 28.43.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 14.99. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 24) to 14.99, marking an increase of 14.99.
- For Earning Retention Ratio (%), as of Mar 25, the value is 71.57. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 71.57, marking an increase of 71.57.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 85.01. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 85.01, marking an increase of 85.01.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.48. This value is within the healthy range. It has decreased from 8.24 (Mar 24) to 4.48, marking a decrease of 3.76.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.62. This value is below the healthy minimum of 3. It has decreased from 5.68 (Mar 24) to 2.62, marking a decrease of 3.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 21,908.96. It has increased from 13,413.39 (Mar 24) to 21,908.96, marking an increase of 8,495.57.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.57. This value exceeds the healthy maximum of 3. It has increased from 6.68 (Mar 24) to 7.57, marking an increase of 0.89.
- For EV / EBITDA (X), as of Mar 25, the value is 21.16. This value exceeds the healthy maximum of 15. It has increased from 19.20 (Mar 24) to 21.16, marking an increase of 1.96.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.67. This value exceeds the healthy maximum of 3. It has increased from 5.70 (Mar 24) to 6.67, marking an increase of 0.97.
- For Retention Ratios (%), as of Mar 25, the value is 71.56. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 71.56, marking an increase of 71.56.
- For Price / BV (X), as of Mar 25, the value is 6.76. This value exceeds the healthy maximum of 3. It has increased from 4.42 (Mar 24) to 6.76, marking an increase of 2.34.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.67. This value exceeds the healthy maximum of 3. It has increased from 5.70 (Mar 24) to 6.67, marking an increase of 0.97.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in ERIS Lifesciences Ltd:
- Net Profit Margin: 12.94%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.74% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.32% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.62
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 47.6 (Industry average Stock P/E: 52.27)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.84
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.94%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Ahmedabad Gujarat 380054 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Amit Bakshi | Chairperson & Managing Director |
| Mr. Krishnakumar Vaidyanathan | COO & Executive Director |
| Mr. Inderjeet Singh Negi | Executive Director |
| Mr. Kaushal Shah | Executive Director |
| Mr. Rajeev Dalal | Independent Director |
| Mr. Sujesh Vasudevan | Independent Director |
| Ms. Kalpana Unadkat | Independent Director |
| Mr. Prashant Gupta | Independent Director |
FAQ
What is the intrinsic value of ERIS Lifesciences Ltd?
ERIS Lifesciences Ltd's intrinsic value (as of 17 January 2026) is ₹1125.54 which is 22.54% lower the current market price of ₹1,453.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹19,791 Cr. market cap, FY2025-2026 high/low of ₹1,910/1,097, reserves of ₹3,078 Cr, and liabilities of ₹7,160 Cr.
What is the Market Cap of ERIS Lifesciences Ltd?
The Market Cap of ERIS Lifesciences Ltd is 19,791 Cr..
What is the current Stock Price of ERIS Lifesciences Ltd as on 17 January 2026?
The current stock price of ERIS Lifesciences Ltd as on 17 January 2026 is ₹1,453.
What is the High / Low of ERIS Lifesciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of ERIS Lifesciences Ltd stocks is ₹1,910/1,097.
What is the Stock P/E of ERIS Lifesciences Ltd?
The Stock P/E of ERIS Lifesciences Ltd is 47.6.
What is the Book Value of ERIS Lifesciences Ltd?
The Book Value of ERIS Lifesciences Ltd is 227.
What is the Dividend Yield of ERIS Lifesciences Ltd?
The Dividend Yield of ERIS Lifesciences Ltd is 0.51 %.
What is the ROCE of ERIS Lifesciences Ltd?
The ROCE of ERIS Lifesciences Ltd is 12.2 %.
What is the ROE of ERIS Lifesciences Ltd?
The ROE of ERIS Lifesciences Ltd is 12.9 %.
What is the Face Value of ERIS Lifesciences Ltd?
The Face Value of ERIS Lifesciences Ltd is 1.00.